Cardiff Oncology, Inc. (CRDF) - צמיחת רווחי EPS רבעונית

Cardiff Oncology, Inc. (CRDF) is focusing on the expansion of onvansertib in combination with baseline oncology therapy to capture market share. This chart of quarterly EPS provided by GURU.Markets confirms operational strength, where the 30.40 mark indicates the profit level. Research and development cover the treatment of lung, prostate, and colorectal tumors. Environmental policy is based on strict laboratory waste disposal and office eco-standards.
פילוחים אנליטיים של חברת Cardiff Oncology, Inc.

Cardiff Oncology, Inc. (CRDF) focuses on overcoming drug resistance through the development of a PLK1 inhibitor for the therapy of KRAS mutations. The metric is calculated as the percentage change in net income per share compared to the same quarter of the previous year. This indicator measures the efficiency of R&D asset monetization and the speed of business scaling. Understanding this trend protects against inflationary losses and emotional overpayment. By analyzing the growth rates of quarterly net income per share, an investor can objectively assess the market reaction to 10-Q reports.